[HTML][HTML] Risk factors for severe COVID-19 outcomes: a study of immune-mediated inflammatory diseases, immunomodulatory medications, and comorbidities in a …
Q Wei, PJ Mease, M Chiorean, L Iles-Shih, WF Matos… - Medrxiv - ncbi.nlm.nih.gov
Background COVID-19 outcomes, in the context of immune-mediated inflammatory diseases
(IMIDs), are incompletely understood. Reported outcomes vary considerably depending on …
(IMIDs), are incompletely understood. Reported outcomes vary considerably depending on …
Risk factors for severe COVID-19 outcomes: a study of immune-mediated inflammatory diseases, immunomodulatory medications, and comorbidities in a large US …
Q Wei, PJ Mease, M Chiorean, L Iles-Shih… - Medrxiv: the Preprint …, 2023 - europepmc.org
Background COVID-19 outcomes, in the context of immune-mediated inflammatory diseases
(IMIDs), are incompletely understood. Reported outcomes vary considerably depending on …
(IMIDs), are incompletely understood. Reported outcomes vary considerably depending on …
Risk factors for severe COVID-19 outcomes: a study of immune-mediated inflammatory diseases, immunomodulatory medications, and comorbidities in a large US …
JJ Hadlock, Q Wei, PJ Mease, M Chiorean, L Iles-Shih… - medRxiv, 2023 - medrxiv.org
Background COVID-19 outcomes, in the context of immune-mediated inflammatory diseases
(IMIDs), are incompletely understood. Reported outcomes vary considerably depending on …
(IMIDs), are incompletely understood. Reported outcomes vary considerably depending on …
Risk factors for severe COVID-19 outcomes: a study of immune-mediated inflammatory diseases, immunomodulatory medications, and comorbidities in a large US …
Q Wei, PJ Mease, M Chiorean… - … : the preprint server …, 2023 - pubmed.ncbi.nlm.nih.gov
Background COVID-19 outcomes, in the context of immune-mediated inflammatory diseases
(IMIDs), are incompletely understood. Reported outcomes vary considerably depending on …
(IMIDs), are incompletely understood. Reported outcomes vary considerably depending on …
Risk factors for severe COVID-19 outcomes: a study of immune-mediated inflammatory diseases, immunomodulatory medications, and comorbidities in a large US …
Q Wei, PPJ Mease, M Chiorean, L Iles-Shih… - Medrxiv: the Preprint …, 2023 - europepmc.org
Background COVID-19 outcomes, in the context of immune-mediated inflammatory diseases
(IMIDs), are incompletely understood. Reported outcomes vary considerably depending on …
(IMIDs), are incompletely understood. Reported outcomes vary considerably depending on …